← Back to patent-cliff list
Meloxicam
Tier C — Watch / tradeMeloxicam
Boehringer Ingelheim
Originator
1995
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COX-2, COX-1
Brand：Vivlodex, Parocin, Mobic, Tenaron, Mobec, Movatec, NanoCrystal, SoluMatrix meloxicam, Mobicox, ANJESO, Xifyrm, Movalis
Indications (approved)：Juvenile rheumatoid arthritis, Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis
Regional status
US
Approved
2000-04-13
EU
Approved
1995-01-01
China
Approved
2000-07-14
Japan
Approved
2004-09-10
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Meloxicam?
Approved indications include: Juvenile rheumatoid arthritis, Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis.
When does the Meloxicam patent expire?
No public expiry year is available for Meloxicam yet; this page updates once verified.
How do I get a quote for Meloxicam intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04